UHY has added RBT CPAs LLP, expanding the Michigan-based Top 50 Firm’s presence to New York’s Hudson Valley and bolstering its wealth management practice.
After debuting on the public markets with $256.3 million and raking in an additional $472 million, Veradermics has emerged as one of biotech’s biggest post-IPO standouts. CEO Reid Waldman credits the weight loss craze for establishing consumer-driven channels.
With the latest round, Roche’s Genentech will have racked up nearly 450 layoffs in California over the last year amid ongoing restructuring. At the same time, the biotech is joining forces with Astex Pharmaceuticals in a deal that could surpass $490 million.
Scribe Therapeutics’ pipeline is immature, with its lead program recently greenlit for first-in-human testing. The biotech is working on CRISPR-based therapies for cardiometabolic diseases.
Plus, CCH Axcess adds complex document ingestion and interpretation; TaxStatus launches Planning Observations to automate discovery; and other accounting tech news and updates.
Accountants are justly proud to be the economy’s “most trusted advisor,” but if you’re doing just what you’ve always done, then that trust you’ve developed is at risk.
As the July 4 launch date nears when clients can start contributing to Trump accounts, advisors discussed pros and cons of this method to save for children.